新型抗血小板药在真实世界中预防再发心肌梗死的有效性
该病例参照研究基于PGRx-ACS注册,纳入1047例再发心肌梗死病例和2234例匹配参照,比较替格瑞洛、普拉格雷与氯吡格雷对再发致死和非致死性心肌梗死的风险。结果显示替格瑞洛和普拉格雷的OR分别为0.65和0.71,替格瑞洛在首次STEMI或NSTEMI中风险降低更明显。
要点
- 与氯吡格雷相比,替格瑞洛和普拉格雷均显著降低再发心肌梗死风险。
- 替格瑞洛在首次STEMI或NSTEMI患者中风险降低幅度更大。
- ≥70岁患者中替格瑞洛仍显示显著获益,普拉格雷未达显著。
核心结论
- 真实世界研究显示,替格瑞洛和普拉格雷较氯吡格雷显著降低再发心肌梗死风险,替格瑞洛降低幅度更大,尤其在首次STEMI或NSTEMI中。
研究设计与样本
- 病例参照研究,基于PGRx-ACS注册,纳入1047例再发心肌梗死病例和2234例按索引ACS类型、日期、年龄和性别匹配的参照。
- 采用多因素条件logistic回归评估替格瑞洛和普拉格雷对比氯吡格雷的OR(95%CI),校正阿司匹林使用和心血管危险因素。
主要发现
- 与氯吡格雷相比,替格瑞洛和普拉格雷的再发心肌梗死OR分别为0.65(95%CI 0.52-0.81)和0.71(95%CI 0.53-0.96)。
- 索引ACS为首次MI时,替格瑞洛OR 0.50(95%CI 0.38-0.67),普拉格雷OR 0.66(95%CI 0.45-0.95)。
- 索引ACS为首次STEMI时,替格瑞洛OR 0.39(95%CI 0.24-0.62),普拉格雷OR 0.44(95%CI 0.26-0.75)。
- 索引ACS为首次NSTEMI时,替格瑞洛OR 0.63(95%CI 0.43-0.92),普拉格雷OR 1.20(95%CI 0.69-2.07)。
- 索引ACS为再发ACS时,替格瑞洛OR 1.11(95%CI 0.72-1.72),普拉格雷OR 0.82(95%CI 0.44-1.54)。
临床怎么用
- 在真实临床实践中,对ACS后预防再发心肌梗死,替格瑞洛和普拉格雷可较氯吡格雷提供更优选择。
- 对于首次STEMI或NSTEMI患者,替格瑞洛可能带来更大幅度的再发心肌梗死风险降低。
- ≥70岁患者使用替格瑞洛仍与再发心肌梗死风险降低相关。
局限性
- 作者指出效应幅度较大可能归因于潜在残余混杂或高于试验报告疗效的真实有效性。
- 研究为观察性病例参照设计,可能存在未测量混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare ticagrelor and prasugrel with clopidogrel for recurrent fatal and non-fatal myocardial infarction (reMI) in real-life conditions. METHODS: Case-referent study using the Pharmacoepidemiological General Research eXtension (PGRx)-acute coronary syndrome (ACS) registry. Cases were patients with reMI from a cohort with index ACS or external to the cohort (same sites). Referents from the cohort, without recurrent event, were matched on index ACS type and date, age and sex with reMI cases. Multivariate conditional logistic regression assessed the OR (95% CI) for reMI associated with ticagrelor and prasugrel vs clopidogrel, adjusted for aspirin use and cardiovascular risk factors. RESULTS: 1047 cases and 2234 matched referents were included. Compared with clopidogrel, ticagrelor and prasugrel were associated with respective ORs of 0.65 (95% CI 0.52 to 0.81) and 0.71 (95% CI 0.53 to 0.96) for reMI occurrence. ORs for ticagrelor and prasugrel vs clopidogrel were: 0.50 (95% CI 0.38 to 0.67) and 0.66 (95% CI 0.45 to 0.95), 0.39 (95% CI 0.24 to 0.62) and 0.44 (95% CI 0.26 to 0.75), 0.63 (95% CI 0.43 to 0.92) and 1.20 (95% CI 0.69 to 2.07), 1.11 (95% CI 0.72 to 1.72) and 0.82 (95% CI 0.44 to 1.54) when index ACS was a first MI, a first ST-elevated MI (STEMI), a first non-STEMI and a recurrent ACS, respectively, and 0.63 (95% CI 0.45 to 0.87) and 0.77 (95% CI 0.41 to 1.45) for patients aged ≥70 years. CONCLUSIONS: This real-world study showed a significant reduction of reMI with new antiplatelets compared with clopidogrel, ticagrelor being associated with a greater decrease of risk notably for first, either STEMI or non-STEMI. The larger magnitude of effect may be attributed to potential residual confounding or higher effectiveness compared with efficacy reported in trials (EMA Post Authorisation Study Registry Number EUPAS5905).
引用
- Grimaldi-Bensouda L, Danchin N, Dallongeville J, et al. Effectiveness of new antiplatelets in the prevention of recurrent myocardial infarction. Heart. 2018. PMID: 29535227. doi:10.1136/heartjnl-2017-312534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。